FGEN / FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study

While a contentious topic, investors seeking long-term success must frequently consider stocks to sell. Similar to changing the oil in a combustion-po more_horizontal

FibroGen (FGEN) falls 22.7% as its late-stage study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy fails to more_horizontal

FibroGen Inc (NASDAQ:FGEN) plummeted some 27% lower in Wednesday's early deals after revealing that its intended treatment for Duchenne muscular dystr more_horizontal

Shares of FibroGen Inc. FGEN, +3.23% fell 23% premarket on Wednesday after the company said its investigational treatment for Duchenne muscular dystro more_horizontal

The heavy selling pressure might have exhausted for FibroGen (FGEN) as it is technically in oversold territory now. In addition to this technical meas more_horizontal

FibroGen, Inc. (NASDAQ:FGEN ) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants David DeLucia - Head of Corporate FP&A / more_horizontal

The headline numbers for FibroGen (FGEN) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compa more_horizontal

FibroGen (FGEN) came out with a quarterly loss of $0.65 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0. more_horizontal